Browse Articles
Discover research articles across all indexed journals
Conservative Oxygen for Unresponsive Patients after Cardiac Arrest
Human macrophage adhesion is significantly higher on SIBS based glaucoma microshunts than on common intraocular lens materials in vitro
Daraxonrasib, a RAS(ON) multi-selective inhibitor vs chemotherapy in previously treated metastatic pancreatic adenocarcinoma (mPDAC): Primary and final analysis from the phase 3 RASolute 302 study.
LBA5 Background: Available 2L therapies offer limited clinical benefit in mPDAC with reported mPFS of 3–4 mo and mOS of 6–7 mo. Aberrant RAS pathway activation is the key driver of PDAC, with oncogenic RAS mutations (mut) identified in >90% of cases, most commonly at codon G12. Daraxonrasib is an oral, RAS(ON) multi-selective, tri-complex inhibitor of the active, GTP-bound state of mutant and wild type RAS. Methods: RASolute 302 (NCT06625320) is a global, randomized, open-label, Ph 3 study in pts with 2L mPDAC and ECOG PS 0-1. Pts were randomized 1:1 to receive daraxonrasib 300 mg PO QD or investigator’s choice of SOC cytotoxic chemo. Dual primary endpoints were OS and PFS by BICR in the RAS G12 mutant (RAS G12) population. Key secondary endpoints included OS and PFS by BICR in the overall population, ORR by BICR in RAS G12 and overall populations. Results: 248 pts were randomized to daraxonrasib and 252 to chemo. Baseline characteristics were balanced between arms. At data cutoff (Feb 10, 2026; mFU: 8.5 mo), all primary and key secondary endpoints were met. Statistically significant, clinically meaningful improvements in OS and PFS were observed with daraxonrasib vs chemo in the RAS G12 and overall populations (Table). Gr ≥3 TRAEs occurred in 43.6% of pts receiving daraxonrasib vs 57.5% receiving chemo. The most common (≥10%) Gr ≥3 TRAEs were rash (13.7%) and stomatitis (12.0%) for daraxonrasib; neutrophil decrease (18.2%) and anemia (16.4%) for chemo. TRSAEs occurred in 10.8% of pts receiving daraxonrasib vs 18.7% receiving chemo. Discontinuation due to TRAEs occurred in 1.2% of pts for daraxonrasib vs 11.2% for chemo. Median/mean daraxonrasib dose intensity was 93.1%/84.7%. Conclusions: Daraxonrasib demonstrated unprecedented improvements in OS and PFS vs chemo in pts with 2L mPDAC with or without an identified tumor RAS mut. Daraxonrasib was generally well tolerated, with a manageable safety profile and with no new safety signals. Results support daraxonrasib as the new SOC for 2L mPDAC. Clinical trial information: NCT06625320 . RAS G12 Overall b Daraxonrasibn=228 Chemo n=231 Daraxonrasib n=248 Chemo n=252 OS Median; mos(95% CI) 13.2(10.0–NE) 6.6(5.4–8.2) 13.2(10.0–NE) 6.7(5.8–8.0) HR(95% CI)P-value 0.40(0.30-0.54)<0.0001 0.40(0.30-0.53)<0.0001 PFS a Median; mos(95% CI) 7.3(6.3–8.1) 3.5(2.9–3.8) 7.2(5.7–7.5) 3.6(2.9–4.2) HR(95% CI)P-value 0.45(0.34-0.59)<0.0001 0.49(0.38-0.64)<0.0001 ORR a %(95% CI) 33.2(27.0–39.9) 11.8(7.8–16.8) 31.6(25.8–38.0) 11.2(7.5–15.9) a By BICR. b RAS G12, G13 or Q61 mut or no RAS mut identified.
Synthesis of bundle copolymers as an emergent class of copolymer architecture
Biomimetic Synthesis of Seven Halenaquinone Meroterpenoids
Exa-cel in Children with Transfusion-Dependent β-Thalassemia or Sickle Cell Disease
Development of chemically modified clinoptilolite granules for enhanced ammonia removal
BREAKWATER: Progression-free and overall survival analyses of first-line (1L) encorafenib + cetuximab (EC) + FOLFIRI in BRAF V600E-mutant metastatic colorectal cancer (mCRC).
LBA3503 Background: Leucovorin/5-FU in combination with oxaliplatin (FOLFOX) or irinotecan (FOLFIRI) are common chemotherapies (chemo) used in 1L treatment (tx) of mCRC. In patients (pts) with BRAF V600E-mutant mCRC, BREAKWATER Phase 3 demonstrated clinically meaningful and statistically significantly improved ORR by blinded independent central review (BICR), PFS by BICR, and OS with 1L EC+mFOLFOX6 vs chemo ± bevacizumab (bev) (Kopetz Nat Med 2025; Elez N Engl J Med 2025). The BREAKWATER safety lead-in previously showed that EC+FOLFIRI was tolerable with promising antitumor activity. BREAKWATER Cohort 3 was therefore conducted to study EC+FOLFIRI. The primary endpoint (EP) of BREAKWATER Cohort 3 was met, demonstrating clinically meaningful and statistically significant improvement in confirmed ORR by BICR with EC+FOLFIRI (64.4%) vs FOLFIRI±bev (39.2%; control) (odds ratio 2.76 [95% CI 1.42, 5.35; one-sided P =0.001]) (Kopetz ASCO GI 2026). Reported here are PFS by BICR (key secondary EP), and updated OS and safety data from BREAKWATER Cohort 3. Methods: Eligible pts in Cohort 3 had untreated BRAF V600E-mutant mCRC, measurable disease (RECIST 1.1), and ECOG PS 0-1. Pts were randomized 1:1 to receive EC+FOLFIRI or control. The primary EP was ORR by BICR. The key secondary EP was PFS by BICR; other secondary EPs included OS and safety. Results: 147 pts were randomized to EC+FOLFIRI or control; the median follow-up for PFS was 18.0 and 14.4 mo, respectively, for OS it was 20.6 and 20.7 mo, respectively (data cutoff: Jan 6, 2026). Baseline demographics and disease characteristics were generally balanced between arms. EC+FOLFIRI demonstrated a clinically meaningful and statistically significant PFS improvement vs control, meeting the key secondary EP (Table). Prolonged OS was observed (Table). The median duration of study tx was 67.9 wk for EC+FOLFIRI and 32.1 wk for control. Discontinuation of chemo (± bev as appropriate for the respective tx arms) due to AEs was similar between arms (14% [EC+FOLFIRI] vs 10% [control]). Conclusions: BREAKWATER Cohort 3 demonstrated clinically meaningful and statistically significant ORR and PFS improvements and prolonged OS with EC+FOLFIRI vs control. The safety profile was consistent with that known for each agent with no new safety signals. EC+FOLFIRI expands practice-changing standard-of-care options to deliver pt-centered care for pts with BRAF V600E-mutant mCRC. Clinical trial information: NCT04607421 . EC+FOLFIRI (n=73) Control (n=74) mPFS (95% CI), mo 15.2 (13.6, NE) 8.3 (6.9, 9.8) PFS HR a (95% CI) 0.44 (0.27, 0.70)One-sided P =0.0002 mOS (95% CI), mo NE (21.0, NE) 20.3 (13.2, NE) OS HR a (95% CI) 0.56 (0.34, 0.94) 18-mo OS rate (95% CI), % 72.0 (60.0, 80.9) 54.5 (42.0, 65.4) n=71 n=68 Serious TEAEs, % 49 44 Maximum Grade 3/4 TEAEs, % 70 81 NE, not estimable; TEAE, tx-emergent adverse event. a Stratified by ECOG PS (0 vs 1) at randomization.
Flexural phonon instability defines intrinsic van der Waals elastic limits in the interlayer direction
Ring-Opening Metathesis Polymerization of Caged FLP Monomers and Uncaged Alkene Macromonomers
Carbocisteine or Hypertonic Saline for Acute Respiratory Failure
Knowledge, attitudes, and practices of anesthesiology healthcare professionals regarding crisis resource management in Shanghai, China: a cross-sectional study
A randomized, open-label, parallel-controlled phase 3 trial of benmelstobart plus chemotherapy and anlotinib for first-line treatment of advanced non-squamous non–small cell lung cancer.
LBA8507 Background: PD-1/PD-L1 inhibitors plus chemotherapy remain standard first-line therapy for EGFR/ALK/ROS1-wild type advanced non-squamous non-small cell lung cancer (nsq-NSCLC). Pre-clinical data suggest angiogenesis inhibitors may potentiate immune checkpoint inhibitors (ICIs). This phase 3 trial evaluated sequential benmelstobart (anti-PD-L1 mAb) plus chemo followed by benmelstobart plus anlotinib versus standard therapy for PFS improvement in this patient population. Methods: TQB2450-III-11 (NCT05346952) is a randomized, open-label, parallel-controlled phase 3 trial. Eligible patients were diagnosed with locally advanced (stage IIIB/C, unfit for surgery or curative-intent chemoradiotherapy) or metastatic nsq-NSCLC. Previous systemic treatment for advanced disease was not allowed. Other key inclusion criteria included ECOG PS of 0-1, aged 18-75 and no EGFR mutations, no ALK or ROS1 rearrangements. Patients were stratified by PD-L1 TPS level (<1%/1-49%/≥50%) and randomized 1:1 to receive benmelstobart or tislelizumab plus platinum and pemetrexed for 4 cycles, then followed by maintenance with benmelstobart plus anlotinib and pemetrexed or tislelizumab plus pemetrexed until disease progression or unacceptable toxicities. Anlotinib dosing was 10 mg, while benmelstobart or tislelizumab was given at a dose of 1200 mg or 200 mg Q3W. The primary endpoint was PFS by independent review committee according to the RECIST version 1.1. Results: From January 24, 2022 to May 8, 2023, 596 eligible patients were randomized 1:1 to benmelstobart group and tislelizumab group. Baseline characteristics were well balanced between two groups. Median PFS was significantly improved in benmelstobart group (14.42 months, 95% CI, 12.35–NE) versus tislelizumab group (8.34 months, 95% CI, 6.97–12.39), HR 0.67 (95% CI, 0.52–0.86; P = 0.0017). The subgroup analysis showed that PFS benefit favored benmelstobart group in almost all subgroups, particularly in patients with ECOG PS 0 (HR 0.36, 0.20-0.65) and PD-L1 TPS <1% (HR 0.61, 0.43-0.86). OS was immature. Safety profiles were similar in two groups. Treatment-emergent adverse events of any grade was 92.28% (benmelstobart group) and 90.94% (tislelizumab group) respectively. ≥Grade 3 treatment-related adverse events was 56.38% (benmelstobart group) and 48.66% (tislelizumab group). Immune-related adverse events was 19.13% (benmelstobart group) and 18.46% (tislelizumab group). Conclusions: Benmelstobart in combination with chemotherapy followed by sequential combination with anlotinib significantly improved PFS compared to tislelizumab in combination with chemotherapy followed by sequential tislelizumab, with a manageable safety profile. It might be a new first-line treatment for nsq-NSCLC. Clinical trial information: NCT05346952 .
Natural language processing models for patient-centered summaries of prostatectomy pathology reports
Ramelteon for prevention of postoperative delirium in elderly cancer patients: A randomized, double-blind, placebo-controlled multicenter trial, JORTC-PON02/J-SUPPORT2103/NCCH2103.
LBA12002 Background: Delirium is a common and serious complication after major cancer surgery in older adults. Current guidelines, including the American Psychiatric Association guideline, do not recommend routine pharmacological prevention because of insufficient high-quality evidence. Ramelteon, a melatonin receptor agonist with a favorable safety profile, has suggested potential benefit in critically ill populations but has shown inconsistent results for prevention of postoperative delirium. Methods: This randomized, double-blind, placebo-controlled multicenter phase III trial enrolled cancer patients aged ≥65 years undergoing surgery under general anesthesia. Patients received ramelteon 8 mg or placebo nightly from 4–8 days before surgery through postoperative day 4. Randomization used minimization with prespecified stratification factors (age ≥75 years, surgical duration ≥6 h, benzodiazepine use, and study site). Guideline-based multicomponent delirium prevention care was implemented in all patients. The planned sample size was 678 patients aged ≥75 years (primary analysis set) plus 88 aged 65–74 years. The primary endpoint was DSM-5–defined delirium within 5 days after surgery. Between-group differences were analyzed using a Cochran–Mantel–Haenszel test adjusted for stratification factors. Results: Among patients aged ≥75 years, postoperative delirium occurred in 22.47% (71/316) of patients receiving ramelteon and 22.76% (71/312) receiving placebo, with no significant difference between groups (adjusted risk difference, ramelteon minus placebo, 0.05%; 95% CI, -6.50% to 6.59%; P = 0.9881). Among patients aged ≥65 years, delirium occurred in 22.54% (80/355) in the ramelteon group and 21.19% (75/354) in the placebo group (adjusted risk difference, ramelteon minus placebo, 1.57%; 95% CI, -4.52% to 7.65%; P = 0.6098). Conclusion: In this phase III randomized controlled trial, ramelteon did not reduce the incidence of postoperative delirium in older adults undergoing major cancer surgery, and these findings do not support routine pharmacological prevention with ramelteon in this setting. Clinical trial information: jRCTs031210673. Clinical trial information: jRCTs031210673 . Delirium within 5 days after surgery. Item Description Primary endpoint result (≥75 y) 22.47% (71/316) with ramelteon vs 22.76% (71/312) with placebo Secondary endpoint result (≥65 y) 22.54% (80/355) with ramelteon vs 21.19% (75/354) with placebo
Glutathione-Mediated Biomimetic NO Activation with Coordination Capsules for NH <sub>3</sub> and α-Amino Acid Electrosynthesis
An adversarial-resilient intrusion detection framework for internet of medical things (IoMT) using digital twin-enabled behavioral threat modeling and federated hybrid ensemble learning
Concurrent thoracic radiotherapy (TRT), platinum/etoposide chemotherapy, and durvalumab immunotherapy in extensive-stage (ES) small cell lung cancer (SCLC): A phase III trial.
LBA8005 Background: A phase III trial indicated a survival benefit of TRT after chemotherapy in ES SCLC. A synergistic effect of concurrent radiotherapy and immunotherapy has been proposed and retrospective studies suggest that TRT improves survival in ES SCLC patients receiving chemoimmunotherapy (chemo-ICI). The main aim of this phase III trial was to investigate whether adding TRT to chemo-ICI improves overall survival (OS) in ES SCLC. Methods: Eligible patients were ≥18 years, had ECOG performance status (PS) 0-1 and disease stage III-IV (TNM 8) ineligible for curative chemoradiotherapy and were randomized 1:1 to chemo-ICI plus TRT («TRT») or chemo-ICI alone («C-I»), stratified by presence of liver and brain metastases. Patients received 4 courses of carboplatin (AUC 5), etoposide (100 mg/m 2 iv day 1-3 or 100 mg/m 2 iv day 1 plus 200 mg/m 2 po days 2-4) and durvalumab 1500 mg q3w, followed by durvalumab 1500 mg q4w until progression, unacceptable toxicity or patients wished to discontinue. TRT of 30 Gy/10 fractions to thoracic lesions started 21-28 days after day 1 of the 1st chemo-ICI cycle. Prophylactic cranial irradiation of 25-30 Gy/10-15 fractions was considered for those responding to chemo-ICI. Primary endpoint was OS, secondary endpoints include overall response rates (ORR), progression free survival (PFS) and toxicity. To show an increase in 1-year survival rates from 53% to 66% with a 2-tailed α of 0.05 and a β of 0.20, 128 patients were required in each group. Results: Enrolment started in January 2022 and was prematurely discontinued in September 2025 according to recommendations by the independent Data and Safety Monitoring Committee due to more serious adverse events (AE) in the TRT group and futility. By then, 228 patients from 20 European hospitals were randomized (TRT: n =115, C-I: n =113). Median age was 68 (range 39-84), 50.4% were female, 37.7% had PS 0, 96.1% stage IV disease, 39.9% metastases to the liver and 28.1% to the brain. Treatment groups were well balanced. Mean number of chemo-ICI courses was 3.6, mean number of total durvalumab courses 7.5 (range 1-30) and 91.3% in the TRT group received TRT. TRT did not improve OS (median 10.0 [TRT] vs. 11.1 months, HR 1.12, 95% CI 0.82-1.54, p=0.47), ORR (TRT: 88.5%, C-I: 89.6%, p=0.79) or PFS (median 5.1 [TRT] vs. 5.1 months, HR 1.09, 95% CI 0.83-1.44, p=0.53). Overall, there were more AEs in the TRT group (87.8% vs. 69.9%, p=0.006), but not more grade 3-4 AEs (TRT: 21.1%, C-I: 17.5%, p=0.33). Esophagitis occurred in 47.8% and grade 3-4 esophagitis in 10.4% of the TRT group. There were more deaths from other causes than SCLC in the TRT group (14.8% vs. 3.5%, p=0.003), though not significantly more when excluding deaths occuring before TRT commenced (9.6% vs. 3.5%, p=0.067). Conclusion: The addition of TRT after the first cycle of chemo-ICI did not improve treatment outcomes in ES SCLC. Clinical trial information: NCT05223647 .